Synthesis and Characterization of AP5346, a Novel Polymer-Linked Diaminocyclohexyl Platinum Chemotherapeutic Agent

Bioconjugate Chemistry - Tập 17 Số 5 - Trang 1270-1279 - 2006
Paul Sood1, Kyle Thurmond2, Jeremy E. Jacob2, Lynda K. Waller2, George O. Silva2, D. Scott Stewart2, David P. Nowotnik2
1Access Pharmaceuticals, Inc., 2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207, USA.
2Access Pharmaceuticals, Inc., 2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207

Tóm tắt

Từ khóa


Tài liệu tham khảo

Rosenberg B., 1965, Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698−699

Weiss R. B., 1993, New cisplatin analogues in developement. A review. Drugs 46, 360−377

Natile G., 2001, Coord. Chem. Rev. 216−, 217

Jones A. L., 1991, Comparison of dexamethasone and ondansetron in the prophylaxis os emesis induced by moderately emetogenic chemotherapy. Lancet 338, 483−487

Smith D. B., 1991, Comparison of ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 338, 487−490

Cubeddu L. Z., 1990, N. Engl. J. Med., 322, 10.1056/NEJM199003223221204

Marty M., 1990, N. Engl. J. Med., 322, 10.1056/NEJM199003223221205

Ito K., 1999, Jpn. J. Clin. Oncol., 29

Hambley T. W., 1997, Coord. Chem. Rev., 166, 10.1016/S0010-8545(97)00023-4

Reedijk J., 1996, Increased understanding in platinum antitumour chemistry. Chem. Commun. 801−806

Calvert A. H., 1989, J. Clin. Oncol., 7, 10.1200/JCO.1989.7.11.1748

Gamelin E., 2002, Clinical aspects and molecular basis of oxaliplatin neurotoxicity:  current management and development of preventative measures. Semin. Oncol. 29 (suppl 15), 21−23

Seymour L. W., 1992, Crit. Rev. Ther. Drug Carrier Syst., 9

Duncan R., 1997, Polymer therapeutics for tumour specific delivery. Chem. Ind. (London), 262−264

Matsumura Y., 1986, A new concept for macromolecular therapeutics in cancer chemotherapy:  mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46 (12), 6387−6392

Gianasi E., 1999, Eur J Cancer, 35, 10.1016/S0959-8049(99)00030-1

Vasey, P. A., Kaye, S. B., Morrison, R., Twelves, C., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., Burtles, S., Fraier, D., Cassidy, J., and Frigerio, E. (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]:  first member of a new class of chemotherapeutic agents- drug-polymer conjugates.Clin. Cancer. Res. 5(1), 83−94.

Julyan P. J., 1999, J. Controlled Release, 57, 10.1016/S0168-3659(98)00124-2

Caiolfa V. R., 2000, J. Controlled Release, 65, 10.1016/S0168-3659(99)00243-6

Meerum Terwogt, J. M., ten Bokkel Huinink, W. W., Schellens, J. H., Schot, M., Mandjes, I. A., Zurlo, M. G., Rocchetti, M., Rosing, H., Koopman, F. J., and Beijnen, J. H. (2001) Phase I clinical and pharmacokinetic study of PNU 166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.Anticancer Drugs 12, 315−323.

Duncan R., 1999, US Patent, 5, 965

Jun Y. J., 2005, J. Inorg. Biochem., 99

Siegmann-Louda D. W., 2004, Polymeric platinum containing drugs in the treatment of cancer. Macromolecules Containing Metal and Metal-like Elements, 191

Thurmond K. B., II, 2005, ACS Symposium Series 923 (Polymer Drug Delivery, 154

Rice J. R., 2006, Preclinical efficacy and pharmacokinetics of AP5346, a novel DACH-platinum tumor-targeting drug delivery system. Clin. Cancer Res. 12, 2248−2254

Rejmanova P., 1977, Aminolyses of monomeric and polymeric 4-nitrophenyl esters of N-methacryloamino acids. Makromol. Chem. 178, 2159−2168

Berners-Price S., 1992, J. Chem. Soc., Chem. Commun. 789−791.

Appleton, T. (1984) Reactions of platinum (II) aqua complexes. 1. Multinuclear (195Pt,15N,31P) NMR study of reactions between the cis-diamminediaquaplatinum (II) cation and the oxygen donor ligands hydroxide, perchlorate, nitrate, sulfate, phosphate and acetate.Inorg. Chem.23, 3514−3521.

Yeong-Sang K., 2004, J. Inorg. Biochem., 98, 104

Smit A., 2005, Evaluation of cisplatin and a novel platinum polymer conjugate for drug toxicity and drug distribution in mice. Anti-Cancer Drugs 16, 501−506

Sood P., US Patent Appl. US 2004/0175387 A1.

Pinciroli V., 1997, Magn. Reson. Chem., 35, 8, 10.1002/(SICI)1097-458X(199701)35:1<2::AID-OMR24>3.0.CO;2-D

Gibson D., 1990, Multinuclear (195Pt, 15N, 13C) NMR studies of the reactions between cis-diaminediaquaplatinum (II) Complexes and aminomalonate. Inorg. Chem. 29, 5125−5129

Kirvan G. E., 1985, Formation and NMR spectra of platinum (II)-tripeptide complexes. Inorg. Chem. 24, 3017−3021

Nagao N., 1997, Platinum (II) complexes with diglycine:  X-ray crystal structure, 15N NMR spectra, and growth-inhibitory activity against mouse meth A solid tumor in vivo. Inorg. Chem. 36, 4195−4201